Journal article
A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer
Kunning Wang, Enxiao Li, Rita A Busuttil, Joseph C Kong, Sharon Pattison, Joseph JY Sung, Jun Yu, Emad M El-Omar, Julie A Simpson, Alex Boussioutas
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | SAGE PUBLICATIONS LTD | Published : 2020
Abstract
Background: The association between the survival or efficacy of chemotherapy and the Lauren subtype of gastric cancer (GC) remains unclear. We aimed to clarify whether patients with different Lauren subtypes have different survival after treatment with systemic chemotherapy: intestinal gastric cancer (IGC) patients survived better than patients with mixed type gastric cancer (MGC) or diffuse gastric cancer (DGC) after treatment with systemic chemotherapy. Patients & methods: Relevant studies for the meta-analysis were identified through searching Pubmed, Embase, Cochrane and Ovid up to March 2020. We also included our own prospectively collected cohort of patients that were followed over a 1..
View full abstractGrants
Awarded by National Natural Science Foundation of China
Funding Acknowledgements
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project was supported by grant 81702421 from the National Natural Science Foundation of China (to Kunning Wang) and by China Scholarship Council (CSC) 201606285152.